Stockscreener 앱 받기
23.49
5.81%
-1.45
전일 마감가:
$24.94
열려 있는:
$25.33
하루 거래량:
113.51K
Relative Volume:
0.81
시가총액:
$646.00M
수익:
-
순이익/손실:
$-69.47M
주가수익비율:
-4.1967
EPS:
-5.5973
순현금흐름:
$-73.92M
1주 성능:
-6.86%
1개월 성능:
-1.39%
6개월 성능:
+4.54%
1년 성능:
+0.00%
1일 변동 폭
$23.13
$25.34
1주일 범위
$23.13
$25.90
52주 변동 폭
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
명칭
Lenz Therapeutics Inc
전화
858-925-7000
주소
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
23.49 | 646.00M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-27 | 개시 | Raymond James | Outperform |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-04-10 | 개시 | Citigroup | Buy |
| 2024-03-27 | 개시 | Piper Sandler | Overweight |
| 2023-02-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-25 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-14 | 개시 | BTIG Research | Buy |
| 2022-03-22 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 개시 | Morgan Stanley | Overweight |
| 2021-07-20 | 개시 | SVB Leerink | Outperform |
모두보기
Lenz Therapeutics Inc 주식(LENZ)의 최신 뉴스
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - Defense World
LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k - Yahoo Finance UK
Citi maintains Buy on LENZ Therapeutics, target at $44 By Investing.com - Investing.com Canada
Citi maintains Buy on LENZ Therapeutics, target at $44 - Investing.com
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
916 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.7%Should You Sell? - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by SG Americas Securities LLC - Defense World
The Presbyopia Market Size to Reach USD 2,513.0 Million by 2035, Impelled by Technological Advancements in Diagnostic Tools - BioSpace
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Target Price from Brokerages - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Trading 8% HigherWhat's Next? - MarketBeat
Leerink Partnrs Has Negative Outlook of LENZ FY2025 Earnings - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5.1%What's Next? - MarketBeat
LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat
Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings - Defense World
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - News & Insights
Yankuang Energy Group Company Limited (OTCMKTS:YZCAY) Sees Large Decrease in Short Interest - Defense World
Myopia Pipeline 2024: Detailed Clinical Trials - openPR
LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday - Defense World
Barclays PLC Sells 1,835 Shares of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) - Defense World
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight - EIN News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat
Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat
Trio-Tech International (NYSE:TRT) Coverage Initiated by Analysts at StockNews.com - Defense World
Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Lenz Therapeutics New Becomes Oversold (LENZ) - Nasdaq
Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
Head to Head Contrast: Allied Resources (ALOD) versus Its Peers - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
SkyWater Technology, Inc. (NASDAQ:SKYT) Shares Purchased by Barclays PLC - Defense World
NI Holdings, Inc. (NASDAQ:NODK) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Acquires 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Neumora plummets on depression drug data - BioPharma Dive
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St
Lenz Therapeutics Inc (LENZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lenz Therapeutics Inc 주식 (LENZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 21 '24 |
Buy |
15.03 |
998,009 |
15,000,075 |
3,319,339 |
0.27%
3.05%
자본화:
|
볼륨(24시간):